DD-723 Phase II clinical trial (Prostate)
Phase 2
- Conditions
- Patients with suspected prostate cancer
- Registration Number
- JPRN-jRCT2080220862
- Lead Sponsor
- DAIICHISANKYO Co.,Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- Male
- Target Recruitment
- 75
Inclusion Criteria
Patients with suspected prostate cancer
- Patients whose most recent PSA level is between 4.0 ng/mL and 20 ng/mL
- Patients aged between 20 and 80 years at the time of informed consent
Exclusion Criteria
- Items listed on the package insert (including absolute contraindications, careful administration, and precautions) to ensure safety.
- Items related to safety and ethics
- Items related to surgery, procedures, and treatment that are considered to influence efficacy and safety assessment for this drug
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effectiveness of contrast effect
- Secondary Outcome Measures
Name Time Method The detection rate of prostate cancer, and assessment of the degree of malignancy